TY - JOUR AU - Ruchdaphornkul, Phornthep AU - Kittikowit, Wipawee AU - Opanuruk, Jurin PY - 2010/12/01 Y2 - 2024/03/29 TI - Quinolone Treatment in High Serum Prostate Specific Antigen in Patient with Pathological Prostatitis JF - Insight Urology JA - Insight Urol VL - 31 IS - 2 SE - Original article DO - UR - https://he02.tci-thaijo.org/index.php/TJU/article/view/252400 SP - 106-111 AB - <div class="page" title="Page 2"><div class="layoutArea"><div class="column"><p><strong>Introduction:</strong> High prostate specific antigen (PSA) is the most common indication for prostatic biopsy to detect prostate cancer in Chulalongkorn hospital. However, this procedure has some complications such as pain, bleeding and septicemia. In some high PSA patients require more than once of biopsy, if the pathologic report is benign or inflammation. Thus the author assume that quinolone treatment should be treat in patient with pathological prostatitis inflammation before taking next serum PSA. It should be decrease if the patient has alone prostatitis inflammation.</p><p><strong>Methods:</strong> The present study recruited 79 males with pathological prostatitis who had high PSA. Patient was randomized to 2 groups. The first group had quinolone treatment for 4 weeks and the other had no treatment. PSA change after 3 month was evaluated and compared.</p><p><strong>Results:</strong> 66% of patient response to antibiotic treatment. PSA in treatment group was significantly decreased with mean PSA difference -1.60+3.48 ng/ml (p=0.007). Mean PSA difference of control group was 0.38+1.94 ng/ml (p= 0.22). There was no significant change of PSA in control group.</p><p><strong>Conclusion:</strong> Quinolone treatment in pathological prostatitis statistically significant reduce serum PSA. Patient who have prostatitic inflammation should treat with quinolone before taking next serum PSA. It may reduce unnecessary biopsy.</p></div></div></div> ER -